Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Lack of Value for Cisplatin Added to Mitomycin-Doxorubicin Combination Chemotherapy for Carcinoma of Unknown Primary Site A Randomized Trial

Eagan, Robert T., M.D.; Therneau, Terry M., Ph.D.; Rubin, Joseph, M.D.; Long, Harry J., M.D.; Schutt, Allan J., M.D.

American Journal of Clinical Oncology: February 1987 - Volume 10 - Issue 1 - p 82–85
ORIGINAL ARTICLE: PDF Only
Buy

Fifty-five patients with metastatic carcinomas of unknown primary site (50 adenocarcinomas) were randomized, after stratification, to treatment with either mitomycin and dox-orubicin (MA) or mitomycin, doxorubicin, and cisplatin (MAP). There was a moderate but nonsignificant improvement in regression frequency (14 vs. 27%) and a slight but also nonsignificant worsening of survival (median 5.5 months vs. median 4.6 months) by the addition of cisplatin at 60 mg/m2 to the MA regimen.

From the Division of Medical Oncology (R.T.E., J.R., H.J.L., A.J.S.), and Medical Research Statistics (T.M.T.), Mayo Clinic, Rochester, Minnesota.

© Lippincott-Raven Publishers.